A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days ...

Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company currently valued at $32.66 million, recently executed a series of stock ...

Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial ...

Passage Bio is outsourcing future analytical testing services in a cost-cutting move that will further cut its workforce, a ...

Passage Bio (NASDAQ:PASG) just reported results for the fourth quarter of 2023. Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -40 cents.